General thoracic surgery
Data acquisition for the histoculture drug response assay in lung cancer

https://doi.org/10.1016/j.jtcvs.2006.06.030Get rights and content
Under an Elsevier user license
open archive

Objective

Application of the histoculture drug response assay for lung cancer was investigated by using data acquired from lung cancer specimens.

Methods

From May 1994 through February 2005, histoculture drug response assay data were obtained from 359 lung cancer specimens held in our institute. We examined chemosensitivities of the tissues to cisplatin, doxorubicin, mitomycin C, 5-fluorouracil, docetaxel, paclitaxel, etoposide, irinotecan, and gemcitabine. Cutoff inhibition rates were determined with each drug for non–small cell lung cancer and were used to calculate predictabilities for chemotherapy responses.

Results

The evaluability of the histoculture drug response assay was high at 97.4%. Good predictability, including true-positive and true-negative rates of 73.2% and 100%, respectively, with an accuracy of 83.0%, was observed.

Conclusion

The histoculture drug response assay appears to be applicable to non–small cell lung cancer for the prediction of responses to chemotherapy.

CTSNet classification

10

Abbreviation and Acronyms

HDRA
histoculture drug response assay
NSCLC
non–small cell lung cancer
SCLC
small cell lung cancer

Cited by (0)